Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study.
J Rheumatol
; 2024 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-38950957
ABSTRACT
OBJECTIVE:
To report the real-world experience on the use of ANI in refractory SLE.METHODS:
Multicenter retrospective study involving 9 Italian SLE referral centers participating in a compassionate use program for the use of ANI in active adult SLE patients in whom all the available treatment choices failed, were not tolerated or contraindicated.At baseline, at 1, 3, 6, 9 and 12 months of treatment, overall and organ specific disease activity, flares, daily glucocorticoid (GC) dose, and adverse events were recorded.RESULTS:
A total of 26 patients were enrolled. At 4 weeks after starting ANI, a significant decrease in SLEDAI-2K (p=0.005), SLEDAS (p=0.005) and PGA (p=0.001) was recorded, and the same trend was maintained over time. A significant reduction in CLASI-activity (p<0.001) and in tender (p=0.026) and swollen (p=0.017) joint count was also recorded. At 3 months of follow-up, 33% of patients already achieved a remission state, while 46% were in LLDAS; at 6 months, 50% were in remission and 80% in LLDAS. A significant reduction in the mean GC daily dose was observed, starting from week 4 (p=0.04). A total of 4 disease flares according to the SELENA-SLEDAI Flare Index were recorded (three mild-moderate and one severe). Overall, 4 out of 20 patients with at least 24 weeks of follow-up (20%) were considered "non responders".CONCLUSION:
This study provides a real-world experience on the use of ANI in refractory SLE patients, confirming its rapid effectiveness and an overall acceptable safety profile.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Rheumatol
Year:
2024
Document type:
Article
Affiliation country:
Italia